Blog
How can AI improve patient outcomes in clinical trials?
20/02/2024
Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered whether AI can help with achieving orphan drug status, recent trends in clinical trial design, how AI can […]
Can AI help with achieving orphan drug status?
13/02/2024
Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered how AI can demonstrate the potential of the pipeline to investors and how AI could disrupt clinical development […]
How does AI-enabled causal modelling support discussions with potential investors?
06/02/2024
Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered what AI-enabled causal modelling is, how it is different from other models, and where you might want to […]
Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?
31/01/2024
Recent announcements suggest large pharma companies are betting big on AI. AstraZeneca recently announced a $247 million deal with an AI vendor to support identifying new oncology drug candidates[1]. Sanofi has announced a collaboration with two separate AI vendors, worth up to $1 billion[2] and $140 million to ‘accelerate discovery of biotherapeutics’[3] and discover small […]
CRO Outsourcing in Clinical Trials: Key Considerations for Sponsors
06/04/2023
CRO outsourcing is common practice in clinical trials; as the global clinical research market becomes ever more competitive, small to mid-size pharmaceutical and biotech companies must rely on the expertise, services and facilities of specialist clinical research organisations (CROs) and functional service providers (FSPs) to support their clinical development programs. By outsourcing to CROs with […]
Common challenges in bioanalytical method development
06/04/2023
The development of bioanalytical methods and subsequent quantification of analytes in a range of biological matrices is fundamental to the drug discovery and development process. Having a reliable and robust methodology, for all target species, including human, plays a key role in understanding how investigational drugs are metabolised following administration. By accurately evaluating both the […]
Clinical Considerations for First-in-Human (FIH) and Early Phase Clinical Trials
06/04/2023
You are coming close to having completed your nonclinical studies and you are beginning to think about your next steps. But exactly what are those? Chances are you are moving into unknown territory with your asset, and you may even have a crucial milestone to consider. How do you navigate your way through the regulatory […]
